Xeljanz
FDA Warns of Serious Risks, Including Death, With JAK Inhibitors
The FDA is requiring the addition of warnings about increased risks for cancer, serious cardiovascular events and ...
SEPTEMBER 28, 2021
JAK Inhibitors, IL-6 Blockers for COVID-19: Where Do They Fit?
Another JAK inhibitor appears effective in reducing death and respiratory failure in patients hospitalized with ...
JULY 7, 2021
Early Safety Results Show Increased Risk for Serious Heart Issues, Cancer From Arthritis Drug
The FDA reported preliminary results from a safety trial of the arthritis drug tofacitinib, showing increased risk ...
FEBRUARY 8, 2021
Tofacitinib Data Shed Light on DVT/PE Rates
Clinicians and patients with ulcerative colitis, rheumatoid arthritis, psoriatic arthritis or ankylosing ...
SEPTEMBER 30, 2020
FDA Warns of Increased Risk for Blood Clots, Death With Higher Dose of Arthritis and Ulcerative Colitis Drug Tofacitinib
The FDA has issued new warnings about an increased risk for blood clots and death associated with the 10-mg ...
AUGUST 1, 2019
